Home524804 • BOM
add
Aurobindo Pharma Ltd
Nakaraang pagsara
₹1,223.95
Sakop ng araw
₹1,221.00 - ₹1,243.00
Sakop ng taon
₹959.05 - ₹1,592.55
Market cap
729.53B INR
Average na Volume
13.22K
P/E ratio
20.19
Dividend yield
-
Primary exchange
NSE
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
(INR) | Set 2024info | Y/Y na pagbabago |
---|---|---|
Kita | 77.96B | 7.99% |
Gastos sa pagpapatakbo | 34.02B | 13.51% |
Net na kita | 8.17B | 7.95% |
Net profit margin | 10.48 | -0.10% |
Kita sa bawat share | 14.00 | 9.12% |
EBITDA | 15.77B | 16.15% |
Aktuwal na % ng binabayarang buwis | 32.34% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
(INR) | Set 2024info | Y/Y na pagbabago |
---|---|---|
Cash at mga panandaliang investment | 68.68B | -3.93% |
Kabuuang asset | 480.94B | 9.50% |
Kabuuang sagutin | 172.09B | 9.41% |
Kabuuang equity | 308.85B | — |
Natitirang share | 583.84M | — |
Presyo para makapag-book | 2.31 | — |
Return on assets | — | — |
Return on capital | 7.81% | — |
Cash Flow
Net change in cash
(INR) | Set 2024info | Y/Y na pagbabago |
---|---|---|
Net na kita | 8.17B | 7.95% |
Cash mula sa mga operasyon | — | — |
Cash mula sa pag-invest | — | — |
Cash mula sa financing | — | — |
Net change in cash | — | — |
Malayang cash flow | — | — |
Tungkol
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer. Wikipedia
Itinatag
1986
Headquarters
Website
Mga Empleyado
26,015